Avatrombopag Meleate
99%
- Product Code: 97031
CAS:
677007-74-8
| Molecular Weight: | 765.73 g./mol | Molecular Formula: | C₃₃H₃₈Cl₂N₆O₇S₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8°C, airtight, dry |
Product Description:
Avatrombopag maleate is primarily used in the treatment of thrombocytopenia, a condition characterized by abnormally low levels of platelets in the blood. It is specifically indicated for patients with chronic liver disease who are scheduled to undergo a medical or dental procedure, as these patients are at a higher risk of bleeding due to low platelet counts. The drug works by stimulating the production of platelets in the bone marrow, thereby reducing the risk of bleeding during and after the procedure.
Additionally, avatrombopag maleate is used in the management of chronic immune thrombocytopenia (ITP) in patients who have had an insufficient response to other treatments. In this context, it helps to increase platelet counts to a level that reduces the risk of spontaneous bleeding.
The drug is typically administered orally, making it convenient for outpatient use. Its efficacy and safety profile have been established through clinical trials, making it a reliable option for patients with these specific conditions.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.050 | 10-20 days | ฿1,890.00 |
+
-
|
| 0.250 | 10-20 days | ฿6,174.00 |
+
-
|
| 1.000 | 10-20 days | ฿17,550.00 |
+
-
|
Avatrombopag Meleate
Avatrombopag maleate is primarily used in the treatment of thrombocytopenia, a condition characterized by abnormally low levels of platelets in the blood. It is specifically indicated for patients with chronic liver disease who are scheduled to undergo a medical or dental procedure, as these patients are at a higher risk of bleeding due to low platelet counts. The drug works by stimulating the production of platelets in the bone marrow, thereby reducing the risk of bleeding during and after the procedure.
Additionally, avatrombopag maleate is used in the management of chronic immune thrombocytopenia (ITP) in patients who have had an insufficient response to other treatments. In this context, it helps to increase platelet counts to a level that reduces the risk of spontaneous bleeding.
The drug is typically administered orally, making it convenient for outpatient use. Its efficacy and safety profile have been established through clinical trials, making it a reliable option for patients with these specific conditions.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :